{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:39:18Z","timestamp":1792474758050,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Perioperative immunotherapy has become the standard of care in patients with high\u2010risk muscle\u2010invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter study comprised 97 patients undergoing removal of primary tumors, followed by adjuvant nivolumab therapy with a potential follow\u2010up period \u2265\u200912\u2009months. Patients were divided according to the primary tumor location: bladder cancer (BC),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200966 (68%); UTUC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931 (32%). Multivariable Cox regression analyses were applied to identify prognostic factors for disease\u2010free survival (DFS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Before surgery, 38% of patients had an estimated glomerular filtration rate (eGFR)\u2009&lt;\u200950\u2009mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      , but this proportion increased to 57% at nivolumab initiation with 19% of UTUC having eGFR\u2009&lt;\u200930. The overall DFS at 6\u2009months was 61.5%. DFS did not differ significantly between BC and UTUC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.83). On multivariable analyses, a higher absolute eosinophil count was significantly associated with worse DFS (HR 2.24; 95% CI, 1.24\u20134.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), while primary tumor location was not. Immune\u2010related adverse events (irAEs) of adrenal insufficiency and hypophysitis occurred in 8% and 4% of patients, respectively, with grade \u2265\u20093 occurring at 3.3\u201318.3\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjuvant nivolumab therapy may provide comparable oncological outcomes between BC and UTUC. Baseline eosinophil count was an independent prognosticator for DFS. The incidences of adrenal insufficiency and hypophysitis appeared higher in our real\u2010world data. Clinicians should recognize these irAEs due to nonspecific symptoms and considerable variability in time of onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70664","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:02:59Z","timestamp":1792472579000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle\u2010Invasive Urothelial Carcinoma"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-2457","authenticated-orcid":false,"given":"Satoshi","family":"Katayama","sequence":"first","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8369-9712","authenticated-orcid":false,"given":"Tatsushi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-6569","authenticated-orcid":false,"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Department of Urology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2104-0058","authenticated-orcid":false,"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4759-7871","authenticated-orcid":false,"given":"Tomofumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-8262","authenticated-orcid":false,"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9821-9407","authenticated-orcid":false,"given":"Tomoaki","family":"Yamanoi","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-543X","authenticated-orcid":false,"given":"Takehiro","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0926-1897","authenticated-orcid":false,"given":"Kazuma","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Murao","sequence":"additional","affiliation":[{"name":"Department of Urology Hiroshima City Hiroshima Citizens Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nakada","sequence":"additional","affiliation":[{"name":"Department of Urology National Hospital Organization Iwakuni Clinical Center  Yamaguchi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-2669","authenticated-orcid":false,"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Hospital  Shimane Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-762X","authenticated-orcid":false,"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Urology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0712","authenticated-orcid":false,"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6793-7416","authenticated-orcid":false,"given":"Shingo","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0002-1592","authenticated-orcid":false,"given":"Kensuke","family":"Bekku","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-2192","authenticated-orcid":false,"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Hospital  Shimane Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-2482","authenticated-orcid":false,"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"2","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JU.0000000000002242","article-title":"Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience Over 3,347 Cases","volume":"207","author":"Mitra A. P.","year":"2022","journal-title":"Journal of Urology"},{"issue":"22","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab Versus Placebo in Muscle\u2010Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin D. F.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High\u2010Risk Muscle\u2010Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"Galsky M. D.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease\u2010Free Survival Analysis for Patients With High\u2010Risk Muscle\u2010Invasive Urothelial Carcinoma From the Randomized CheckMate 274 Trial by PD\u2010L1 Combined Positive Score and Tumor Cell Score","volume":"83","author":"Galsky M. D.","year":"2023","journal-title":"European Urology"},{"issue":"1","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant Nivolumab Versus Placebo for High\u2010Risk Muscle\u2010Invasive Urothelial Carcinoma: 5\u2010Year Efficacy and ctDNA Results From CheckMate 274","volume":"37","author":"Galsky M. D.","year":"2026","journal-title":"Annals of Oncology"},{"issue":"4","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040491","article-title":"The Role of Eosinophils, Eosinophil\u2010Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC","volume":"15","author":"Omero F.","year":"2025","journal-title":"Biomolecules"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1155\/jskc\/2561307","article-title":"Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta\u2010Analysis","volume":"2025","author":"Gambichler T.","year":"2025","journal-title":"Journal of Skin Cancer"},{"issue":"4","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant Atezolizumab Versus Observation in Muscle\u2010Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open\u2010Label, Randomised, Phase 3 Trial","volume":"22","author":"Bellmunt J.","year":"2021","journal-title":"Lancet Oncology"},{"issue":"1","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab Versus Observation in Muscle\u2010Invasive Urothelial Carcinoma","volume":"392","author":"Apolo A. B.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-024-01114-4","article-title":"Adjuvant Immune Checkpoint Inhibitors for Muscle\u2010Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta\u2010Analysis, and Network Meta\u2010Analysis","volume":"20","author":"Yanagisawa T.","year":"2025","journal-title":"Targeted Oncology"},{"issue":"3","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.urolonc.2024.08.003","article-title":"Adjuvant Immunotherapy in High\u2010Risk Muscle Invasive Urothelial Carcinoma: A Systematic Review and Meta\u2010Analysis of Randomized Clinical Trials","volume":"43","author":"Oscar\u2010Thompson L.","year":"2025","journal-title":"Urologic Oncology"},{"issue":"1","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/iju.15319","article-title":"Adjuvant Immunotherapy in Patients With Renal Cell Carcinoma and Urothelial Carcinoma: A Systematic Review and Network Meta\u2010Analysis","volume":"31","author":"Mori K.","year":"2024","journal-title":"International Journal of Urology"},{"issue":"4","key":"e_1_2_11_14_1","first-page":"452","article-title":"Stage\u2010Dependent Survival in Patients Treated With Neoadjuvant Chemotherapy and Radical Cystectomy","volume":"75","author":"D'Andrea D.","year":"2023","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"30","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1111\/1759-7714.15100","article-title":"Pretreatment Eosinophil Counts as a Predictive Biomarker in Non\u2010Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors","volume":"14","author":"Takeuchi E.","year":"2023","journal-title":"Thoracic Cancer"},{"issue":"1","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-01457-6","article-title":"Peripheral Eosinophils and Immunotherapy Response in Patients With Recurrent or Metastatic HNSCC","volume":"15","author":"Qin Y.","year":"2025","journal-title":"Scientific Reports"},{"issue":"7","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/CJI.0000000000000372","article-title":"Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti\u2010PD\u20101\/PD\u2010L1 Checkpoint Inhibitors","volume":"44","author":"Mota J. M.","year":"2021","journal-title":"Journal of Immunotherapy"},{"issue":"12","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s10147-025-02909-9","article-title":"Elevated Proportion of Eosinophils Predicts Immune\u2010Related Adverse Events and Improved Survival in Patients With Gastric Cancer Treated With Nivolumab","volume":"30","author":"Matsumoto S.","year":"2025","journal-title":"International Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the Tumor Microenvironment: Implications for Cancer Immunotherapy","volume":"21","author":"Ghaffari S.","year":"2023","journal-title":"Journal of Translational Medicine"},{"issue":"9","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41590-022-01291-2","article-title":"Eosinophil\u2010Lymphocyte Interactions in the Tumor Microenvironment and Cancer Immunotherapy","volume":"23","author":"Grisaru\u2010Tal S.","year":"2022","journal-title":"Nature Immunology"},{"issue":"10232","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (The POUT Trial): A Phase 3, Open\u2010Label, Randomised Controlled Trial","volume":"395","author":"Birtle A.","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update","volume":"87","author":"Masson\u2010Lecomte A.","year":"2025","journal-title":"European Urology"},{"issue":"2","key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta\u2010Analysis","volume":"4","author":"Barroso\u2010Sousa R.","year":"2018","journal-title":"JAMA Oncology"},{"issue":"2","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary Dysfunction Induced by Immune Checkpoint Inhibitors Is Associated With Better Overall Survival in Both Malignant Melanoma and Non\u2010Small Cell Lung Carcinoma: A Prospective Study","volume":"8","author":"Kobayashi T.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"10236","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab With or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo\u2010Controlled Phase 3 Trial","volume":"395","author":"Galsky M. D.","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis Induced by Immune Checkpoint Inhibitors: A 10\u2010Year Assessment","volume":"14","author":"Di Dalmazi G.","year":"2019","journal-title":"Expert Review of Endocrinology & Metabolism"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241257874","article-title":"Endocrine Adverse Events in Patients With Cancer Receiving Perioperative Immune Checkpoint Blockade: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"16","author":"Zhou S.","year":"2024","journal-title":"Therapeutic Advances in Medical Oncology"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:03:03Z","timestamp":1792472583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/iju.70664"],"URL":"https:\/\/doi.org\/10.1111\/iju.70664","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70664"}}